JP4522586B2 - 新規のベンゾフラン誘導体、それらの製造方法及び薬剤としてのそれらの使用 - Google Patents

新規のベンゾフラン誘導体、それらの製造方法及び薬剤としてのそれらの使用 Download PDF

Info

Publication number
JP4522586B2
JP4522586B2 JP2000583898A JP2000583898A JP4522586B2 JP 4522586 B2 JP4522586 B2 JP 4522586B2 JP 2000583898 A JP2000583898 A JP 2000583898A JP 2000583898 A JP2000583898 A JP 2000583898A JP 4522586 B2 JP4522586 B2 JP 4522586B2
Authority
JP
Japan
Prior art keywords
group
alkyl
formula
amino
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2000583898A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002530403A5 (cg-RX-API-DMAC7.html
JP2002530403A (ja
Inventor
カルニアトー ドニ
アール.ガデック トマス
グールベスト ジャンフランソワ
クノル ヨッヘン
ペイマン アヌシルヴァン
シー.ボダリー セイラ
Original Assignee
アベンティス・ファーマ・ソシエテ・アノニム
ジェネンテック, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アベンティス・ファーマ・ソシエテ・アノニム, ジェネンテック, インコーポレイテッド filed Critical アベンティス・ファーマ・ソシエテ・アノニム
Publication of JP2002530403A publication Critical patent/JP2002530403A/ja
Publication of JP2002530403A5 publication Critical patent/JP2002530403A5/ja
Application granted granted Critical
Publication of JP4522586B2 publication Critical patent/JP4522586B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2000583898A 1998-11-24 1999-11-23 新規のベンゾフラン誘導体、それらの製造方法及び薬剤としてのそれらの使用 Expired - Lifetime JP4522586B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR98/14779 1998-11-24
FR9814779A FR2786184B1 (fr) 1998-11-24 1998-11-24 Nouveaux derives du benzofurane, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
PCT/FR1999/002879 WO2000031070A1 (fr) 1998-11-24 1999-11-23 Nouveaux derives du benzofurane, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant

Publications (3)

Publication Number Publication Date
JP2002530403A JP2002530403A (ja) 2002-09-17
JP2002530403A5 JP2002530403A5 (cg-RX-API-DMAC7.html) 2006-12-14
JP4522586B2 true JP4522586B2 (ja) 2010-08-11

Family

ID=9533118

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000583898A Expired - Lifetime JP4522586B2 (ja) 1998-11-24 1999-11-23 新規のベンゾフラン誘導体、それらの製造方法及び薬剤としてのそれらの使用

Country Status (8)

Country Link
US (2) US6458801B1 (cg-RX-API-DMAC7.html)
EP (1) EP1133491B1 (cg-RX-API-DMAC7.html)
JP (1) JP4522586B2 (cg-RX-API-DMAC7.html)
AT (1) ATE232859T1 (cg-RX-API-DMAC7.html)
DE (1) DE69905490T2 (cg-RX-API-DMAC7.html)
ES (1) ES2192870T3 (cg-RX-API-DMAC7.html)
FR (1) FR2786184B1 (cg-RX-API-DMAC7.html)
WO (1) WO2000031070A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1176145A1 (en) * 2000-07-28 2002-01-30 Aventis Pharma Deutschland GmbH Novel guanidino derivatives as inhibitors of cell adhesion
US7078541B2 (en) * 2002-02-07 2006-07-18 Galileo Pharmaceuticals, Inc. Benzofuran derivatives
US6653346B1 (en) * 2002-02-07 2003-11-25 Galileo Pharmaceuticals, Inc. Cytoprotective benzofuran derivatives

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU675680B2 (en) * 1992-10-14 1997-02-13 Merck & Co., Inc. Fibrinogen receptor antagonists
GB9408577D0 (en) * 1994-04-29 1994-06-22 Fujisawa Pharmaceutical Co New compound
ATE227567T1 (de) * 1994-05-27 2002-11-15 Merck & Co Inc Präparate zur hemmung der durch osteoklasten vermittelten knochenresorption
GB9522007D0 (en) * 1995-10-27 1996-01-03 Fujisawa Pharmaceutical Co New compound
US5955495A (en) * 1996-05-03 1999-09-21 Hoffmann-La Roche Inc. Method of treating diseases of the CNS
GB9614347D0 (en) * 1996-07-09 1996-09-04 Smithkline Beecham Spa Novel compounds
DE19629816A1 (de) * 1996-07-24 1998-01-29 Hoechst Ag Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
US5981514A (en) * 1998-02-12 1999-11-09 Somberg; John C. (N-alkyl-N-hydroxymethylamino)alkoxybenzoylbenzofurans and the phosphate esters thereof

Also Published As

Publication number Publication date
ATE232859T1 (de) 2003-03-15
DE69905490D1 (de) 2003-03-27
EP1133491A1 (fr) 2001-09-19
US6586442B2 (en) 2003-07-01
EP1133491B1 (fr) 2003-02-19
US6458801B1 (en) 2002-10-01
US20020187976A1 (en) 2002-12-12
FR2786184A1 (fr) 2000-05-26
WO2000031070A1 (fr) 2000-06-02
JP2002530403A (ja) 2002-09-17
FR2786184B1 (fr) 2002-09-20
DE69905490T2 (de) 2003-07-24
ES2192870T3 (es) 2003-10-16

Similar Documents

Publication Publication Date Title
US6492356B1 (en) Acylguanidine derivatives as inhibitors of bone resorption and as vitronectin receptor antagonists
US6660728B2 (en) Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists
AU752882B2 (en) Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion
AU768206B2 (en) Novel guanidine derivatives as inhibitors of cell adhesion
JP4550286B2 (ja) 新規なアシルグアニジン誘導体、それらの製造方法、薬剤としてのそれらの使用及びそれらを含有する製薬組成物
JP5143989B2 (ja) ビトロネクチン受容体の新規な拮抗薬誘導体
US6458801B1 (en) Benzofurane derivatives, preparation method, use as medicines and pharmaceutical compositions containing same
JP2003532732A5 (cg-RX-API-DMAC7.html)
JP4578685B2 (ja) イミノグアニジン誘導体、それらの製造方法及び薬剤としてのそれらの使用
US6762190B2 (en) Thienylalanine derivatives as inhibitors of cell adhesion
CZ20002672A3 (cs) Sulfonamidové deriváty jako inhibitory kostní resorpce a jako inhibitory buněčné adheze

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061017

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061017

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091124

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20091125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100223

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20100223

RD13 Notification of appointment of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7433

Effective date: 20100223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100223

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100427

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100526

R150 Certificate of patent or registration of utility model

Ref document number: 4522586

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130604

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term